NHS England launches first-ever breast cancer screening campaign
New data has shown that around a third of women do not attend screenings after being invited
Read Moreby Emily Kimber | Feb 18, 2025 | News | 0
New data has shown that around a third of women do not attend screenings after being invited
Read Moreby Jen Brogan | Aug 1, 2024 | News | 0
Combined, ovarian and breast cancer affect over 60,000 women in the UK every year
Read Moreby Jen Brogan | Jul 2, 2024 | News | 0
According to WHO, around 15% of pregnant women will develop an obstetric complication
Read Moreby Jen Brogan | Jul 1, 2024 | News | 0
Breast cancer is the most common cancer in the UK, accounting for 15% of all cancers
Read Moreby Jen Brogan | Apr 18, 2024 | News | 0
Breast cancer was responsible for 2.3 million diagnoses and 670,000 deaths globally in 2022
Read Moreby Jen Brogan | Mar 7, 2024 | News | 0
Secondary breast cancer is an important risk factor after receiving radiotherapy for Hodgkin lymphoma
Read Moreby Jen Brogan | Feb 28, 2024 | News | 0
Breast cancer is responsible for around 47,000 new cases in England every year
Read Moreby Jen Brogan | Dec 1, 2023 | News | 0
Every year, around 55,000 women in the UK are diagnosed with the condition
Read Moreby John Pinching | Dec 7, 2022 | News | 0
Data reinforces potential to deliver new standards across HER2-targetable breast cancer
Read Moreby John Pinching | Jun 21, 2022 | News | 0
Pre-clinical screening technology could increase cancer test numbers by 50 times
Read Moreby John Pinching | Jun 17, 2022 | News | 0
Verzenios in combination with endocrine treats people with early breast cancer who are at high-risk of recurrence
Read Moreby John Pinching | Mar 9, 2022 | News | 0
Trodelvy is accepted for use in mTNBC patients who have already received two or more systemic therapies
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
